Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
30 Leser
Artikel bewerten:
(0)

Pre-market Equity Watch on Health Care Equipment and Supplies Industry -- Research on MELA Sciences, OraSure Technologies, DENTSPLY Intl., and Antares Pharma

LONDON, June 19, 2014 /PRNewswire/ --

On Wednesday, June 18, 2014, the NASDAQ Composite ended at 4,362.84, up 0.59%, the Dow Jones Industrial Average finished the day 0.58% higher at 16,906.62, and the S&P 500 closed at 1,956.98, up 0.77%. The gains were broad based as all the ten sectors finished higher. The S&P 500 Health Care Sector Index ended the day at 694.51, up 0.82%, and the index has advanced 3.36% in the last one month. Investor-Edge has initiated coverage on the following equities: MELA Sciences Inc. (NASDAQ: MELA), OraSure Technologies Inc. (NASDAQ: OSUR), DENTSPLY International Inc. (NASDAQ: XRAY) and Antares Pharma Inc. (NASDAQ: ATRS). Free technical research on MELA, OSUR, XRAY and ATRS can be downloaded upon signing up at:

http://www.investor-edge.com/3969-register

On Wednesday, MELA Sciences Inc.'s stock recorded a trading volume of 0.32 million shares, lower than its three months average volume of 0.39 million shares. The stock finished the day at an intra-day low of $0.36, down 5.24%, and registered an intraday range of $0.36 and $0.39. MELA Sciences Inc.'s shares have lost 7.67% in the past three trading sessions and 6.47% in the last one month. Also, the stock has declined 43.73% on YTD basis. Furthermore, the company's stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $0.64 is above its 50-day moving average of $0.46. Additionally, shares of the company have a Relative Strength Index (RSI) of 43.23. Sign up today to read free research on MELA at:

http://www.investor-edge.com/3969-MELA-19Jun2014.pdf

OraSure Technologies Inc.'s stock gained 1.98%, to close Wednesday's session at $8.76, after hitting a new 52-week high of $8.78. The stock recorded a trading volume of 0.75 million shares, above its three months average volume of 0.60 million shares. Over the last one month and previous three months, OraSure Technologies Inc.'s shares have rallied 45.76% and 7.62%, respectively. Also, from the beginning of 2014, the company's stock has surged 39.27%. The stock is trading above its 50-day and 200-day moving averages. The company stock's 50-day moving average of $6.66 is above its 200-day moving average of $6.55. Further, the company's stock has an RSI of 81.12. Sign up today to read free research on OSUR at:

http://www.investor-edge.com/3969-OSUR-19Jun2014.pdf

On Wednesday, DENTSPLY International Inc.'s stock finished the session 0.25% higher at $47.81. A total of 0.80 million shares were traded, which was below its three months average volume of 0.88 million shares. The stock moved between $47.49 and $47.83 during the session. Over the last one month and past three months, DENTSPLY International Inc.'s shares have advanced 3.06% and 4.21%, respectively. However, the stock has fallen by 1.38% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $46.25 is greater than its 200-day moving average of $46.18. DENTSPLY International Inc.'s stock traded at a PE ratio of 23.86 and has an RSI of 60.24. Sign up today to read free research on XRAY at:

http://www.investor-edge.com/3969-XRAY-19Jun2014.pdf

Shares in Antares Pharma Inc. fluctuated between $3.05 and $3.15 before ending Wednesday's session down 1.58%, at $3.11. The company's stock reported a trading volume of 0.53 million shares, below its three months average volume of 1.52 million shares. Further, shares of Antares Pharma Inc. have gone up 1.30% over the past three trading sessions and 6.14% over the last one month. However, the stock has lost 30.44% on YTD basis. The stock is trading above its 50-day moving average. The stock's 200-day moving average of $3.92 is greater than its 50-day moving average of $2.99. Moreover, shares of the company have an RSI of 57.13. Sign up today to read free research on ATRS at:

http://www.investor-edge.com/3969-ATRS-19Jun2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.